To generate mutations at the APTF-2 target site in the glp-1 promoter we injected the following mix: Cas9 protein (5 g), tracrRNA (0.4 g/l), crRNA (aatgggcggagtatgccacc) (0.4 g/l), ssDNA oligo repair donor (1 g/l), myo-2::mCherry plasmid (4 ng/l) and brought to a 20 l volume with nuclease-free water
Under normal circumstances, the kidneys filter glucose from the blood, but SGLT2 proteins in the proximal tubules reabsorb nearly all of this glucose back into the bloodstream
Patients using semaglutide-containing medications may experience side effects, and these can vary based on individual factors and medical history
Never double up, and follow your provider's instructions
Patients with obesity may be appropriately treated with diabetes-approved GLP-1 RAs if they also have a diagnosis of T2DM, though claims data may not fully capture this information